Jianwei Lu
Nantong Tumor Hospital(CN)
Publications by Year
Research Areas
Gastric Cancer Management and Outcomes, Colorectal Cancer Treatments and Studies, Cancer-related molecular mechanisms research, Lung Cancer Treatments and Mutations, RNA modifications and cancer
Most-Cited Works
- → Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial(2023)555 cited
- → Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study(2021)187 cited
- → m6A RNA modification modulates PI3K/Akt/mTOR signal pathway in Gastrointestinal Cancer(2020)100 cited
- → Preoperative Systemic Immune–Inflammation Index (SII) as a Superior Predictor of Long-Term Survival Outcome in Patients With Stage I–II Gastric Cancer After Radical Surgery(2022)95 cited
- → Long non-coding RNA Loc554202 regulates proliferation and migration in breast cancer cells(2014)79 cited
- → First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis(2022)68 cited
- → CXCL12-CXCR4 Promotes Proliferation and Invasion of Pancreatic Cancer Cells(2013)68 cited
- → Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients(2021)68 cited
- → Autophagy: novel applications of nonsteroidal anti‐inflammatory drugs for primary cancer(2017)64 cited
- → Long non-coding RNA XIST promotes the development of esophageal cancer by sponging miR-494 to regulate CDK6 expression(2018)61 cited